In pathological cardiac hypertrophy caused by pressure overload in vivo or by phenylephrine (PE) treatment of NRCMs in vitro, the expressions of KLF15 and BCAA degradation enzymes were decreased (Supplementary Fig. 3a–d), whereas glucose utilization increased6,30. The gene discussed is KLF15; the disease is cardiac hypertrophy.